Abstract: The present invention relates to the treatment of a woman for endometriosis comprising the administration of IFN-gamma, a cytokine antagonist and/or an anti-estrogenic agent.

Abstract: The present invention relates to a method of identifying a novel protein by exposing, in vivo or in vitro, a cell source or a mixture of cell sources in culture to one or more stimulatory factors. The invention is based on the discovery that exposure of cells to stimulatory factors results in expression of novel proteins, including secreted proteins and intracellular proteins and that the exposed cells can be used to easily identify large numbers of rare transcripts encoding novel proteins.

Abstract: The present invention is directed to a method of treating estrogen responsive breast cancer in an individual comprising administering to an individual a therapeutically effective estradiol inhibiting amount of interferon gamma (IFN-?) and/for a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists. The invention is based upon the surprising discovery that IFN-? and/or a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists inhibit estradiol production in human adipocytes. This discovery is not only important because it allows for the treatment and/or prevention of estrogen dependent breast cancer using IFN-?, TNF antagonists or IL-1 antagonist each alone or in combination, but also because IFN-? and/or TNF antagonists and/or IL-1 antagonists can be used in conjunction with standard anti-estrogen therapy, e.g., tamoxifen and/or aromatase inhibitor, to result in lower estrogen levels than seen with standard anti-estrogen therapy alone.

Abstract: The present invention is directed to the identification genes that are expressed at a higher level in certain FSH or FSH Mimetic treated cells than in otherwise identical untreated cells. Genes that are expressed at a higher level in FSH or FSH Mimetic treated cells than untreated cells (“FSH or FSH Mimetic stimulated genes”) are of interest, in part, because FSH or FSH Mimetics can or could influence a wide range of cellular processes and responses in reproduction, including steroidogenesis and gamatogenesis.

Abstract: The present invention is directed to the identification of genes that are expressed at a higher level in certain TNF & IFN treated cells than in otherwise identical untreated cells. Genes that are expressed at a higher level in TNF & IFN treated cells than untreated cells (“TNF & IFN stimulated genes”) are of interest, in part, because TNF & IFN can or could influence a wide range of cellular processes and responses for antiviral activity. The identified TNF & IFN stimulated genes and the proteins they encode can be used: 1) as therapeutic agents which modulate a cellular process or response that is influenced by TNF & IFN; 2) as targets for use in high throughput screening and the development of therapeutic agents which modulate a cellular process or response that is influenced by TNF & IFN; and 3) as markers which can be used to detect and monitor a cellular process or response that is influenced by TNF & IFN.